title: Collaborations among academia, government, and industry in the diagnostics space: barriers and some ideas for solutions.
abstract: The development and commercialization of diagnostic assays is distinct from that of therapeutic drugs in many important respects; for example, there are more variable regulatory requirements and reduced outside investments for diagnostics. The diagnostics industry has a pro-collaborative stance, because there is considerable mutual benefit in working in partnership with university or government researchers. However, there are substantial barriers to industry-academic collaborations. A Clinical and Translational Science Awards Industry Forum titled "Promoting Efficient and Effective Collaborations Among Academia, Government, and Industry" was held in February 2010, and a session at this forum was organized to list some of the most important barriers to diagnostics development and to discuss some possible solutions.
authors.affiliation: Small Business Innovation Research Development Center, National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD 20892, USA. evansgl@mail.nih.gov
authors.forename: Greg
authors.initials: G
authors.lastname: Evans
authors.forename: Finley
authors.initials: F
authors.lastname: Austin
mesh_terms: D006076:Government; D007221:Industry; D033183:Interdisciplinary Communication; D057170:Translational Research, Biomedical